ICMJE DISCLOSURE FORM

Date:	5/23/2022		
Your Name:	Eugenio De Miguel		
Manuscript Title:	Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis. Results of the ARTESER register		
Manuscript Number (if known):	Click or tap here to enter text.		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1 All support for the present		□ None			
	manuscript (e.g.,	Roche	Grant support for the data inclusion		
	funding, provision of study materials,		Payments were made to the Spanish Rheumatology Foundation		
	medical writing,		Click the tab key to add additional rows.		
	article processing charges, etc.)				
	No time limit for				
	this item.				
		Time frame: past 36 months			
2	Grants or	None			
	contracts from	Lij None			
	any entity (if not	Roche	Payments were done to the Hospital		
	indicated in item		Universitario La Paz. My institution		
	#1 above).		Payments were done to the Madrid		
			Rheumatology Society		
3	Royalties or licenses	□ None X			
1		12/13/2021	ICMJE Disclosure Form		

De Miguel E, et al. RMD Open 2023; 8:e002507. doi: 10.1136/rmdopen-2022-002507

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
4	Consulting fees	□ None		
		Novartis	Personal	
		Lilly	Personal	
		Abbvie	Personal	
		Pfizer, Janssen	Personal	
5	Payment or honoraria for	□ None		
	lectures, presentations, speakers	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly.	Personal	
	bureaus,			
	manuscript writing or educational events			
_				
6	Payment for expert testimony	□ None		
	expert testimony			
7	Support for attending	□ None		
	meetings and/or	Institution		
		Institution AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche,		
	meetings and/or			
	meetings and/or	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche,		
8	meetings and/or	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche,		
8	meetings and/or travel Patents planned,	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly.		
8	meetings and/or travel Patents planned,	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly.		
8	meetings and/or travel Patents planned,	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly.		
8	meetings and/or travel Patents planned,	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None		
8	Participation on a Data Safety	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None		
	Participation on a Data Safety Monitoring Board	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None	Personal	
	Participation on a Data Safety	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None	Personal	
	Participation on a Data Safety Monitoring Board	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None	Personal	
9	Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None None	Personal	
	Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None None None	Personal	
9	Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None None	Personal	
9	Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society,	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None None None	Personal	
9	Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None None None	Personal	
9	Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society,	AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi, Lylly. None None None None	Personal	

2 12/13/2021 ICMJE Disclosure Form

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None X		
13	Other financial or non-financial interests	None		
Please place an "X" next to the following statement to indicate your agreement: Y I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

3 12/13/2021 ICMJE Disclosure Form